Compare Charles River Laboratories Intl. Inc (CRL) vs Flux Power Holdings Inc (FLUX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Flux Power Holdings Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $227.69 (market cap $11.14B), while Flux Power Holdings Inc trades at $0.71 (market cap $15.57M). The key difference: Charles River Laboratories Intl. Inc is far larger — about 715.5× Flux Power Holdings Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Flux Power Holdings Inc nearer its low. Which is the better fit depends on your goals.
| CRL | FLUX | |
|---|---|---|
Market Cap | $11.14B | $15.57M |
Sector | Health | Utilities |
52-Week High | $233.60 | $6.66 |
52-Week Low | $145.57 | $0.72 |
Enterprise Value | $14.00B | $21.74M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
FLUX trades at $0.7304, down 5.94% in the last session, with a bearish technical signal from moving averages. The company reported mixed quarterly results, missing Q3 2026 EPS estimates but beating in Q4 2025. Revenue declined from $66M in 2025 to $51M in 2026, with negative net income margins persisting. Recent developments include the launch of SkyEMS 3.0 AI-powered fleet management software and new executive appointments aimed at growth acceleration.
Despite unanimous analyst buy ratings, FLUX faces significant profitability challenges with negative ROE and ROA. The stock's primary investment opportunity lies in its clean energy technology positioning and strong analyst support, but risks include ongoing losses, revenue contraction, and competitive pressures in the energy storage market that could limit near-term upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Flux Power Holdings Inc
Flux Power designs and manufactures lithium-ion battery packs for industrial vehicles. Its sustainable energy solutions power material handling equipment like forklifts and airport ground support vehicles.
Read more on FLUX →
